Dr. Félix Wagner

Dr. Félix Wagner is one of Luxembourg's most experienced medical oncologists, holding dual appointments at the Centre Hospitalier de Luxembourg (CHL) — the Grand Duchy's flagship public hospital — and Hôpital Kirchberg, a leading private hospital in the capital. With over 22 years of clinical practice in oncology, Dr. Wagner has built a distinguished career treating patients with solid tumours, with particular expertise in breast cancer, lung cancer, and gastrointestinal malignancies. He is known for integrating the latest advances in targeted therapy and immunotherapy into personalised treatment plans tailored to each patient's tumour biology and overall health status.

Dr. Wagner trained at the Université Paris VI Pierre et Marie Curie and completed his oncology fellowship at the Institut Gustave Roussy in Villejuif, France, one of Europe's foremost cancer centres. He subsequently undertook a research sabbatical at the Memorial Sloan Kettering Cancer Center in New York before returning to Luxembourg to establish his clinical oncology practice at the CHL. His international training and research collaborations have given him broad exposure to the most advanced therapeutic paradigms in oncology.

A central aspect of Dr. Wagner's work is his leadership within Luxembourg's cross-border cancer care network. Given Luxembourg's unique geographic position bordering France, Belgium, and Germany, many patients benefit from coordinated care pathways that allow access to specialised oncological procedures, clinical trials, and radiotherapy services across the Greater Region. Dr. Wagner plays a key role in coordinating these pathways and has been instrumental in establishing formal data-sharing agreements with the Institut National du Cancer (INCa) and the GORE oncology network.

Dr. Wagner conducts consultations in French, German, Luxembourgish, and English, reflecting Luxembourg's multilingual society and its significant expatriate and cross-border worker population. He is a committed advocate for transparent communication with patients and families throughout the cancer journey, from diagnosis through treatment and, when needed, into palliative and supportive care.

Dr. Wagner completed his medical degree at the Université Paris VI Pierre et Marie Curie (now Sorbonne Université), Faculty of Medicine, followed by an internal medicine residency in the Paris public hospital network (Assistance Publique-Hôpitaux de Paris). He then undertook a specialisation fellowship in medical oncology at the Institut Gustave Roussy in Villejuif — one of the world's leading comprehensive cancer centres — gaining advanced training in solid tumour oncology, clinical trial design, and translational research. He completed an additional research fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, focusing on breast cancer molecular subtypes and treatment response biomarkers. He holds the designation of Fellow of the European Society for Medical Oncology (FESMO), awarded in recognition of his clinical expertise and contributions to oncology science. Dr. Wagner is also a member of the Groupement des Oncologues de la Région Est (GORE), a cross-border oncology network spanning Luxembourg, Lorraine, Saarland, and Wallonia.

Dr. Wagner's clinical practice focuses on the systemic treatment of solid tumours using chemotherapy, targeted agents, and immunotherapy. In breast cancer — his primary subspecialty — he manages all stages and molecular subtypes, from hormone receptor-positive luminal tumours to HER2-positive disease and triple-negative breast cancer, including patients in the neoadjuvant, adjuvant, and metastatic settings. He has extensive experience with CDK4/6 inhibitors, HER2-directed antibodies, PARP inhibitors, and immune checkpoint inhibitors.

In lung cancer, Dr. Wagner manages both small cell and non-small cell lung cancer, with expertise in selecting patients for EGFR, ALK, ROS1, and PD-L1 directed therapies. For colorectal cancer, he coordinates chemotherapy backbone regimens alongside targeted anti-VEGF and anti-EGFR therapies in collaboration with surgical and radiation oncology colleagues.

Dr. Wagner also leads a palliative oncology service at the CHL, integrating early palliative care principles alongside active tumour treatment, with a focus on symptom management, quality of life, and advance care planning. He chairs the hospital's multidisciplinary tumour board meetings for breast and lung cancers and coordinates referrals to radiotherapy centres and clinical trial sites within Luxembourg and the Greater Region.

Dr. Wagner has published more than 50 peer-reviewed articles in leading oncology journals including the Journal of Clinical Oncology, Annals of Oncology, and the European Journal of Cancer. His research focuses on cross-border oncology care coordination between Luxembourg and its neighbouring countries (France, Belgium, Germany), cancer epidemiology in the Luxembourgish population, and the application of biomarker-driven treatment selection in breast and lung cancer. He has collaborated with the Institut National du Cancer (INCa) on French-Luxembourg cross-border cancer registry data analysis, contributing to publications on cancer incidence, stage at diagnosis, and treatment access disparities across the Greater Region. He is a co-investigator on several ESMO-supported academic clinical trials and has served as a national coordinator for Luxembourg in multicentre European oncology studies. His doctoral research, conducted in collaboration with Gustave Roussy, examined predictive biomarkers of chemotherapy response in triple-negative breast cancer.

Dr. Wagner is experienced in treating patients from across the Greater Region and internationally. Luxembourg's position at the heart of Europe makes it a natural hub for cross-border oncology care, and Dr. Wagner facilitates access for patients from France, Belgium, Germany, and beyond under EU cross-border healthcare directives. EU residents can access his services under the European Health Insurance Card (EHIC) or through S2 authorisations from their home countries' health systems. Non-EU international patients are accommodated through CHL's international patient coordination unit and Hôpital Kirchberg's international services team. Dr. Wagner offers consultations in French, German, Luxembourgish, and English. He also participates in multidisciplinary second-opinion consultations and can review pathology and imaging for patients seeking oncology opinions before committing to a treatment programme.

Dr. Wagner has been recognised by the Société Luxembourgeoise d'Oncologie (SLO) with its annual SLO Award for outstanding contribution to cancer care in Luxembourg. The Centre Hospitalier de Luxembourg awarded him its Clinical Excellence Recognition for his leadership of the multidisciplinary tumour board and his development of palliative oncology services. He holds the Fellow of the European Society for Medical Oncology (FESMO) designation and has served on the ESMO educational faculty for oncology training programmes across Europe. He has been invited to present his research at major international oncology congresses including ASCO, ESMO, and ECCO.